Chronic Liraglutide Therapy Induces an Enhanced Endogenous Glucagon-like Peptide-1 Secretory Response in Early Type 2 Diabetes
January 2017. This study evaluated the impact of chronic liraglutide therapy on endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Fifty-one patients with type 2 diabetes (mean duration, 2.6 years, +/- 1.9 years) were randomized for 48 weeks to subcutaneous liraglutide or placebo. Patients received an oral glucose tolerance test (OGTT) every 12 weeks, with GLP-1 and GIP area under the curve (AUC) measured at 0, 30, 60, 90, and 120 minutes. No between-group differences were observed for AUC GIP. However, a statistically significant 2-fold elevation in postprandial AUC GLP-1 was observed starting at 12 weeks and persisting throughout the trial. The investigators concluded that chronic liraglutide therapy induced a robust, durable, and previously unrecognized enhancement to endogenous GLP-1 response.